We are live on ! Find out more
IGC icon

IGC Pharma
IGC

26 hedge funds and large institutions have $1.31M invested in IGC Pharma in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

338% more call options, than puts

Call options by funds: $197K | Put options by funds: $45K

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

0.52% less ownership

Funds ownership: 6.33% → 5.81% (-0.52%)

10% less funds holding

Funds holding: 29 → 26 (-3)

24% less capital invested

Capital invested by funds: $1.73M → $1.31M (-$422K)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
26
Holders Change
-3
Holders Change %
-10.34%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
7
Closed
7
Calls
$197K
Puts
$45K
Net Calls
+$152K
Net Calls Change
-$31K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$55K
2
Millennium Management
Millennium Management
New York
+$43.8K
3
TSS
Two Sigma Securities
New York
+$19.9K
4
VIA
Vident Investment Advisory
Georgia
+$7K
5
DP
Dearborn Partners
Illinois
+$5K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$60.5K
2
IEFM
IQ EQ Fund Management
Ireland
-$54K
3
BCM
Bridgeway Capital Management
Texas
-$37.3K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$30.2K
5
VF
Virtu Financial
New York
-$24K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
– -$267 -501 -36%
Wells Fargo
27
Wells Fargo
California
– +$14 +27 +9%
Fidelity Investments
28
Fidelity Investments
Massachusetts
– +$160 +300 New
SPIA
29
Steward Partners Investment Advisory
New York
– +$160 +300 New
1
2

IGC Hedge Fund Activity: Q3 2022 in Review

26 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2022, worth a combined $1.31M — down 24% from $1.73M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of IGC and 4 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 7 added.

The largest buyer was Renaissance Technologies, adding an estimated $55K. The largest seller was Citadel Advisors, cutting an estimated $60.5K.

  • 26 institutional investors held IGC Pharma (IGC) as of Q3 2022, down from 29 in Q2 2022.
  • Funds reported $1.31M of IGC Pharma stock for Q3 2022, down 24% quarter-over-quarter.
  • 4 funds opened new IGC Pharma positions in Q3 2022 and 7 closed out, a net change of -3 holders.
  • The largest IGC Pharma buyer in Q3 2022 was Renaissance Technologies, an estimated $55K added.
  • The largest IGC Pharma seller in Q3 2022 was Citadel Advisors, an estimated $60.5K sold.

Based on aggregated 13F filings for Q3 2022.